SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-098534
Filing Date
2024-11-14
Accepted
2024-11-14 16:57:46
Documents
50
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0217946-10q_actinium.htm   iXBRL 10-Q 783663
2 CERTIFICATION ea021794601ex31-1_actinium.htm EX-31.1 10498
3 CERTIFICATION ea021794601ex31-2_actinium.htm EX-31.2 9832
4 CERTIFICATION ea021794601ex32-1_actinium.htm EX-32.1 4188
5 CERTIFICATION ea021794601ex32-2_actinium.htm EX-32.2 4427
6 GRAPHIC image_001.jpg GRAPHIC 90357
  Complete submission text file 0001213900-24-098534.txt   3851275

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE atnm-20240930.xsd EX-101.SCH 27350
8 XBRL CALCULATION FILE atnm-20240930_cal.xml EX-101.CAL 25472
9 XBRL DEFINITION FILE atnm-20240930_def.xml EX-101.DEF 147200
10 XBRL LABEL FILE atnm-20240930_lab.xml EX-101.LAB 305841
11 XBRL PRESENTATION FILE atnm-20240930_pre.xml EX-101.PRE 156416
52 EXTRACTED XBRL INSTANCE DOCUMENT ea0217946-10q_actinium_htm.xml XML 304557
Mailing Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017
Business Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017 (646) 677-3870
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

IRS No.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36374 | Film No.: 241463902
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)